Table 3.
Clinical details of cases histologically assessed for LYPD3 protein expression was compared in malignant (primary and metastatic) breast adenocarcinoma tissue.
| LYPD3 Score | |||
|---|---|---|---|
| Negative | Positive | Chi Square (p-Value) | |
| Age | |||
| <40 | 55 (91.7%) | 5 (8.3%) | 2.885 (0.236) |
| 40–59 | 179 (84.8%) | 32 (15.2%) | |
| >60 | 43 (91.5%) | 4 (8.5%) | |
| Tumour Grade | |||
| 1 | 39 (14.1%) | 2 (4.9%) | 10.034 (0.074) |
| 1–2 | 4 (1.4%) | 1 (2.4%) | |
| 2 | 105 (37.9%) | 19 (46.3%) | |
| 2–3 | 0 (0) | 1 (2.4%) | |
| 3 | 64 (23.1%) | 9 (22%) | |
| Tumour stage | |||
| I | 18 (6.5%) | 2 (4.9%) | 15.712 (0.028) |
| IIA | 102 (36.8%) | 8 (19.5%) | |
| IIB | 32 (11.6%) | 4 (9.8%) | |
| IIIA | 5 (1.8%) | 3 (7.3%) | |
| IIIB | 19 (6.9%) | 3 (7.3%) | |
| IV | 5 (1.8%) | 1 (2.4%) | |
| Oestrogen receptor status | |||
| Negative | 137 (69.2%) | 16 (76.2%) | 0.442 (0.506) |
| Positive | 61 (30.8%) | 5 (23.8%) | |
| HER2 status | |||
| Negative | 162 (81.4%) | 14 (66.7%) | 2.580 (0.108) |
| Positive | 37 (18.6%) | 7 (33.3%) | |
| Tissue pathology status | |||
| Malignant primary breast tumour | 219 (86.9%) | 33 (13.1%) | 3.535 (0.171) |
| Metastasis | 39 (83%) | 8 (17%) | |
| Adjacent normal breast tissue | 19 (100%) | 0 (0%) | |
Significant values are shown in bold and missing data censored.